Panchsheel Organics Past Earnings Performance
Past criteria checks 2/6
Panchsheel Organics has been growing earnings at an average annual rate of 29%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 20.3% per year. Panchsheel Organics's return on equity is 11.3%, and it has net margins of 13.4%.
Key information
29.0%
Earnings growth rate
24.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 20.3% |
| Return on equity | 11.3% |
| Net Margin | 13.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Panchsheel Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,052 | 141 | 65 | 0 |
| 31 Dec 23 | 1,035 | 143 | 66 | 0 |
| 30 Sep 23 | 1,058 | 140 | 66 | 0 |
| 30 Jun 23 | 1,065 | 140 | 59 | 0 |
| 31 Mar 23 | 1,032 | 141 | 62 | 0 |
| 31 Dec 22 | 966 | 141 | 59 | 0 |
| 30 Sep 22 | 842 | 112 | 55 | 0 |
| 30 Jun 22 | 749 | 101 | 54 | 0 |
| 31 Mar 22 | 690 | 84 | 52 | 0 |
| 31 Dec 21 | 582 | 63 | 51 | 0 |
| 30 Sep 21 | 546 | 57 | 50 | 0 |
| 30 Jun 21 | 550 | 57 | 47 | 0 |
| 31 Mar 21 | 496 | 50 | 48 | 0 |
| 31 Dec 20 | 496 | 53 | 49 | 0 |
| 30 Sep 20 | 497 | 52 | 49 | 0 |
| 30 Jun 20 | 474 | 52 | 46 | 0 |
| 31 Mar 20 | 505 | 53 | 50 | 0 |
| 31 Dec 19 | 487 | 48 | 49 | 0 |
| 30 Sep 19 | 507 | 49 | 48 | 0 |
| 30 Jun 19 | 497 | 45 | 46 | 0 |
| 31 Mar 19 | 485 | 40 | 46 | 0 |
| 31 Dec 18 | 492 | 43 | 44 | 0 |
| 30 Sep 18 | 461 | 38 | 46 | 0 |
| 30 Jun 18 | 448 | 37 | 45 | 0 |
| 31 Mar 18 | 424 | 37 | 42 | 0 |
| 31 Dec 17 | 387 | 30 | 44 | 0 |
| 30 Sep 17 | 393 | 31 | 36 | 0 |
| 30 Jun 17 | 403 | 29 | 34 | 0 |
| 31 Mar 17 | 401 | 32 | 35 | 0 |
| 31 Dec 16 | 420 | 32 | 30 | 0 |
| 30 Sep 16 | 396 | 30 | 31 | 0 |
| 30 Jun 16 | 400 | 28 | 29 | 0 |
| 31 Mar 16 | 404 | 30 | 28 | 0 |
| 31 Dec 15 | 385 | 31 | 39 | 0 |
| 30 Sep 15 | 386 | 29 | 38 | 0 |
| 30 Jun 15 | 370 | 26 | 75 | 0 |
| 31 Mar 15 | 358 | 19 | 22 | 0 |
| 31 Dec 14 | 392 | 16 | 36 | 0 |
| 30 Sep 14 | 382 | 12 | 32 | 0 |
| 30 Jun 14 | 381 | 16 | 32 | 0 |
| 31 Mar 14 | 392 | 18 | 33 | 0 |
| 31 Dec 13 | 365 | 12 | 33 | 0 |
| 30 Sep 13 | 348 | 10 | 35 | 0 |
| 30 Jun 13 | 334 | 10 | 33 | 0 |
Quality Earnings: 531726 has high quality earnings.
Growing Profit Margin: 531726's current net profit margins (13.4%) are lower than last year (13.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531726's earnings have grown significantly by 29% per year over the past 5 years.
Accelerating Growth: 531726's earnings growth over the past year (0.3%) is below its 5-year average (29% per year).
Earnings vs Industry: 531726 earnings growth over the past year (0.3%) did not outperform the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: 531726's Return on Equity (11.3%) is considered low.